Caplin Point Laboratories Limited AI Stock Analysis
Want to see IN:CAPLIPOINT full AI Analyst Report?
Caplin Point Laboratories Limited (CAPLIPOINT) AI Stock Analysis
Caplin Point Laboratories Limited
(NSE:CAPLIPOINT)
The overall score of 72 is primarily driven by the company's outstanding financial health, particularly its debt-free balance sheet and efficient capital allocation. This strength is partially offset by a neutral technical outlook suggesting a consolidation phase and a relatively high valuation with a negligible dividend yield. The recent slowdown in revenue growth and gross margin pressure are key risks to monitor.
Caplin Point Laboratories Limited (CAPLIPOINT) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 179.17B
- Dividend Yield
- 0.34%
- Average Volume (3M)
- 13.16K
- Price to Earnings (P/E)
- 25.9
- Beta (1Y)
- 1.12
- Revenue Growth
- 16.84%
- EPS Growth
- 17.02%
- Country
- India
- Employees
- 3,406
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Caplin Point Laboratories Limited Business Overview & Revenue Model
Company Description
Caplin Point Laboratories Limited is a pharmaceutical firm actively involved in the development, manufacture, marketing, and export of both generic medications and proprietary branded products, primarily operating within India. Their extensive produc...
Caplin Point Laboratories Limited Financial Statement Overview
Summary
The company exhibits a robust financial profile, anchored by an exceptionally strong, debt-free balance sheet (Score 95) and consistent profitability. While revenue growth slowed and gross margins compressed, net income expanded 19.6% due to cost discipline, and cash flows remain healthy. The overall financial health is solid, tempered slightly by the top-line deceleration.
Income Statement
78PositiveBalance Sheet
95Very PositiveCash Flow
75Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.87B | 21.87B | 19.40B | 16.96B | 14.68B | 12.71B |
| Gross Profit | 11.15B | 10.50B | 11.38B | 9.40B | 7.89B | 6.99B |
| EBITDA | 8.53B | 8.76B | 6.53B | 5.54B | 4.43B | 3.97B |
| Net Income | 6.41B | 6.41B | 5.36B | 4.57B | 3.76B | 3.00B |
Balance Sheet | ||||||
| Total Assets | 40.45B | 40.45B | 32.09B | 26.98B | 21.91B | 17.36B |
| Cash, Cash Equivalents and Short-Term Investments | 10.07B | 10.07B | 9.03B | 7.88B | 6.50B | 5.13B |
| Total Debt | 46.10M | 46.10M | 50.20M | 19.70M | 54.80M | 21.30M |
| Total Liabilities | 4.15B | 4.15B | 3.22B | 3.51B | 2.84B | 2.26B |
| Stockholders Equity | 35.86B | 35.86B | 28.50B | 23.16B | 18.80B | 14.84B |
Cash Flow | ||||||
| Free Cash Flow | 1.60B | 3.37B | 2.41B | 1.73B | 779.00M | 2.46B |
| Operating Cash Flow | 2.54B | 5.85B | 4.32B | 3.18B | 2.72B | 3.37B |
| Investing Cash Flow | -2.99B | -6.45B | -3.35B | -3.20B | -2.18B | -3.77B |
| Financing Cash Flow | -460.10M | -455.90M | -383.20M | -380.70M | -281.70M | -407.10M |
Caplin Point Laboratories Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAPLIPOINT, the sentiment is Negative. The current price of 2344.45 is below the 20-day moving average (MA) of 2350.20, below the 50-day MA of 2540.35, and above the 200-day MA of 2188.02, indicating a neutral trend. The MACD of -23.70 indicates Negative momentum. The RSI at 43.49 is Neutral, neither overbought nor oversold. The STOCH value of 19.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAPLIPOINT.
Caplin Point Laboratories Limited Peers Comparison
Overall Rating
IN:STAR77Outperform
IN:AKUMS73Outperform
IN:CAPLIPOINT72Outperform
IN:GRANULES72Outperform
IN:PPLPHARMA56Neutral
IN:JUBLPHARMA49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | INR 90.89B | 14.74 | ― | 0.51% | 11.28% | 55.18% | |
| 73Outperform | INR 113.67B | 30.39 | ― | 0.41% | 17.50% | 14.74% | |
| 72Outperform | INR 178.21B | 25.89 | ― | 0.34% | 16.84% | 17.02% | |
| 72Outperform | INR 198.15B | 27.64 | ― | 0.22% | 21.75% | 36.70% | |
| 56Neutral | INR 326.18B | -155.24 | ― | 0.06% | 9.43% | -767.49% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 49Neutral | INR 153.06B | 57.78 | ― | 0.52% | 18.30% | -44.95% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:CAPLIPOINT | Caplin Point Laboratories Limited | 2344.45 | 421.33 | 21.91% | |
| IN:AKUMS | Akums Drugs and Pharmaceuticals Limited | 722.20 | 299.65 | 70.91% | |
| IN:GRANULES | Granules India Limited | 799.65 | 246.95 | 44.68% | |
| IN:JUBLPHARMA | Jubilant Pharmova Limited | 960.95 | -141.29 | -12.82% | |
| IN:PPLPHARMA | Piramal Pharma Limited | 245.00 | 56.15 | 29.73% | |
| IN:STAR | Strides Pharma Science Ltd | 986.00 | 29.28 | 3.06% |
Caplin Point Laboratories Limited Corporate Events
Caplin Point Laboratories Board Approves Unaudited September 2026 Results
Caplin Point Laboratories Limited’s board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The release also included an investor presentation and a limited review report.Standalo...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026
